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Abstract The HIV-1 Rev transactivator is phosphorylated in
vitro by protein kinase CK2 at two residues, Ser-5 and Ser-8;
these sites are also phosphorylated in vivo. Here we show that the
mechanism by which CK2 phosphorylates Rev is unique in several
respects, notably: (i) it is fully dependent on the regulatory,
L-subunit of CK2; (ii) it relies on the integrity of an acidic stretch
of CK2L which down-regulates the phosphorylation of other
substrates; (iii) it is inhibited in a dose-dependent manner by
polyamines and other polycationic effectors that normally
stimulate CK2 activity. In contrast, a peptide corresponding to
the amino-terminal 26 amino acids of Rev, including the
phosphoacceptor site, is readily phosphorylated by the catalytic
subunit of CK2 even in the absence of the L-subunit. These data,
in conjunction with the observation that two functionally inactive
derivatives of Rev with mutations in its helix-loop-helix motif are
refractory to phosphorylation, indicate the phosphorylation of
Rev by CK2 relies on conformational features of distinct regions
that are also required for the transactivator’s biological
activity. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The acronym CK2, derived from the misnomer ‘casein ki-
nase-2’, refers to a Ser/Thr protein kinase physiologically un-
related to casein, whose targeting is speci¢ed by multiple
acidic residues and is able to use either GTP or ATP as a
phosphate donor (reviewed in [1^3]). In addition to phosphor-
ylating Ser/Thr residues on a variety of substrates, it was
recently shown that CK2 is also able to phosphorylate tyrosyl
residues [4,5]. However, the most intriguing feature of CK2 is
probably its enigmatic mode of regulation. At variance with
the majority of protein kinases, the catalytic K and KP sub-
units of CK2 are constitutively active in the absence of second
messengers, activating subunits or phosphorylation events.
Moreover, association of the K and KP subunits with two
regulatory L-subunits, yielding a stable heterotetrameric holo-
enzyme, has di¡erent e¡ects on catalytic activity depending on
the substrate; many substrates, notably small peptides, are
more readily phosphorylated in the presence of L subunits,
while the phosphorylation of other substrates (e.g. calmodu-
lin) is inhibited. This dual role of the L-subunit is believed to
re£ect the presence of distinct domains playing di¡erent and
in some respects opposite roles. These domains have been
mapped by generating L mutants defective in either up- or
down-regulatory properties [6^8] and synthetic fragments of
the L subunit retaining only some of the properties of the full-
size protein [9,10]. Results of these studies demonstrated that
down-regulation is mediated by acidic residues concentrated
in the N-terminal part of the molecule, whose mutation to
alanines suppresses the ability of the L subunit to inhibit cal-
modulin phosphorylation, while it stimulates catalytic activity
toward peptide substrates [6,8]. This acidic region is also re-
sponsible for the interaction of the L subunit with polycationic
molecules, such as histones, polylysine [8] and polyamines
[11], which are known to stimulate the activity of the CK2
holoenzyme at least in part by neutralizing the down-regula-
tory potential of the L subunit.
Despite these ¢ne-tuned modes of regulation, it must be
assumed that CK2 is always constitutively active within the
living cell : this apparent paradox may explain the extraordi-
nary pleiotropy of CK2, whose growing list of substrates cur-
rently includes more than 200 proteins [12]. It is conceivable
therefore that a discrete level of CK2 activity is required at all
stages of di¡erentiation and under all metabolic conditions. It
is also possible that its constitutive activity underlies the im-
puted role of CK2 in pathogenic events, notably neoplasias
and infectious diseases (reviewed in [3,13]). As far as the latter
are concerned, it is remarkable that many viruses exploit host
cell CK2 to phosphorylate their own proteins. This makes
CK2 a potential target for antiviral as well as antineoplastic
therapies [14].
The list of CK2 substrates identi¢ed thus far includes hu-
man immunode¢ciency virus type-1 (HIV-1) proteins, i.e. Vpu
and Rev, whose CK2-mediated phosphorylation was estab-
lished both in vitro and in vivo [15,16]. While the phosphor-
ylation of Vpu has been correlated with its ability to interact
with CD4 [17,18], a crucial step in the viral infection strategy,
nothing is known about the signi¢cance of Rev phosphoryla-
tion, which takes place at two residues close to the N-terminus
of the protein, Ser-5 and Ser-8, the latter of which ful¢ls the
consensus sequence for CK2 targeting and, once phosphory-
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lated, creates the consensus for the phosphorylation of Ser-5
[16]. These phosphorylation sites lie adjacent to an arginine-
rich sequence spanning amino acids 35^50 that is required for
the ability of Rev to accumulate in the nucleus and to bind to
RNA, two properties that are crucial to its functional activity
as a post-transcriptional regulatory factor (reviewed in [19]).
Intriguingly, this domain is also responsible for the ability of
Rev to stimulate CK2 activity toward other protein substrates
[20]. In an attempt to shed light on the mechanism by which
CK2 phosphorylates Rev, we have investigated the e¡ect of
modulators of CK2 activity and of Rev mutations which are
known to impair its function. The results, presented in this
report, highlight the unique behavior of Rev among the
known substrates of CK2 and raise the possibility of selec-
tively inhibiting Rev phosphorylation under conditions that
do not reduce the activity CK2 toward its cellular targets.
2. Materials and methods
2.1. Materials
Recombinant K and L subunits of either wild type or mutated
human CK2 were obtained as previously detailed [21,22]. Native
CK2 puri¢ed from rat liver was prepared as described [23]. Wild
type and mutant Rev proteins were produced in bacteria as GST
fusion proteins from pGEX2T-derived plasmids, isolated by a⁄nity
chromatography using glutathione-Sepharose, and then eluted using
glutathione according to standard protocols [24]. The strategy used to
clone plasmids encoding GST-Rev and GST-Rev38,39R-L is de-
scribed elsewhere [25]. To clone the plasmid expressing GST-Re-
vvloop, a pair of PCR fragments encoding sequences amino-terminal
and carboxy-terminal to the loop were ligated and then subcloned
into the pGEX2T backbone; this cloning approach deleted residues
24^34 and also inserted a leucine codon after residue 35.
A synthetic peptide corresponding to the 26 amino-terminal resi-
dues of Rev was prepared on a 431A (Applied Biosystems) peptide
synthesizer using (£uorenylmethoxy)carbonyl (Fmoc) chemistry with
an N-methylpyrrolidone solvent system [26]. Chain assembly was per-
formed on 0.1 mmol of Rink amide AM resin (0.69 mmol/g) (Nova-
biochem) using Fmoc-protected amino acids activated with a mixture
of 2-(1-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa£uorophos-
phate, N-hydroxybenzotriazole and N-ethyldiisopropylamine in dime-
thylformamide. Side chain protecting groups were removed during
cleavage with a solution containing 95% (v/v) tri£uoroacetic acid,
2.5% (v/v) triisopropylsilane and 2.5% (v/v) water. After cleavage,
peptides were puri¢ed to homogeneity by reversed-phase high-per-
formance liquid chromatography with a linear gradient of 0^60%
acetonitrile. Purity of the synthetic peptides was assessed by matrix-
assisted laser desorption ionization mass spectrometry.
Synthetic peptides reproducing residues 67^93 of Inhibitor-2 and
the central helix residues 68^92 of calmodulin were prepared as pre-
viously described [27,28].
2.2. Phosphorylation assay
Phosphorylation experiments were performed at 37‡C for 10 min in
a 25 Wl ¢nal volume containing 50 mM Tris^HCl pH 7.5, 12 mM
MgCl2, 100 mM NaCl, 20 WM [Q-32P]ATP (speci¢c activity 500^1000
cpm/pmol) and GST-Rev fusion proteins or peptides. The concentra-
tions of the phosphorylatable substrate and the enzyme are speci¢ed
in the ¢gure legends and tables. The reaction was initiated with the
addition of the kinase and was stopped by cooling in ice. Protein
samples were then subjected to SDS^PAGE according to Laemmli
[29], followed by staining with Coomassie brilliant blue and either
autoradiography or radioanalytic scanning on a Canberra-Packard
Instant Imager. Phosphorylation of synthetic peptides was measured
using the phosphocellulose paper procedure [30].
3. Results
The substrate-dependent e¡ect of the L subunit on CK2
activity is exempli¢ed in Fig. 1, which compares the phos-
phorylation of three physiological substrates catalyzed by ei-
ther the catalytic K subunit or the holoenzyme reconstituted
by combining equimolar amounts of the K and the L subunits.
Inhibitor-2 of protein phosphatase 1 (I-2) is readily phosphor-
ylated by CK2K alone and even more rapidly by the holoen-
zyme, denoting a moderate stimulatory e¡ect of the L subunit,
as normally observed with speci¢c peptide substrates of CK2.
In sharp contrast, calmodulin is phosphorylated by CK2K but
not to any appreciable extent by the CK2 holoenzyme, high-
lighting the predominance of the negative regulatory e¡ects of
the L subunit, as has also been reported for a few other pro-
tein substrates of CK2 (see [12]). The behavior of Rev di¡ers
from that of I-2 and is opposite to that of calmodulin: phos-
phorylation, almost undetectable in the presence of CK2K
alone, is triggered by the L subunit upon holoenzyme recon-
stitution. This unique behavior of Rev, as well as the opposite
Fig. 1. Distinct e¡ects of the L subunit on the phosphorylation of
CK2 protein substrates. Recombinant Inhibitor-2 (I-2), calmodulin
(CaM) and Rev (2 Wg) were incubated with [32P]ATP in the pres-
ence of recombinant CK2 K subunit (5 pmol) either alone or previ-
ously mixed with an equimolar amount of L subunit and then sub-
jected to SDS^PAGE through a 15% gel (11% in the case of CaM
and Rev), all as described in Section 2. Polylysine, when present,
was 336 nM. Shown is the resulting autoradiogram with arrows in-
dicating the positions of I-2, CaM and Rev, with Mr 31 kDa, 15.6
kDa and 19 kDa, respectively. The upper band visible in the central
lane of the CaM panel is due to autophosphorylation of the L sub-
unit (Mr 25 kDa) which is inhibited by polylysine.
Table 1
CK2-catalyzed phosphorylation of synthetic peptides spanning the phosphoacceptor sites of Rev, calmodulin and Inhibitor-2 is stimulated to a
similar extent by the L subunit
Peptide Phosphorylation rate (cpm) by Stimulation (fold)
K K2L2
Rev(1^26) MAGRSGDSDEELIRTVRLIKLLYQSN 3 106 12 240 3.94
CaM(68^92) FLTMMARKMKDTDSEEEIREAFRVF 6 016 35 075 5.83
I-2(67^93) IDEPSTPYHSMIGDDDDAYSDTETTEA 17 612 42 798 2.43
Standard RRRAADSDDDDD 11 572 48 132 4.15
Peptides (40 WM) were phosphorylated and 32P incorporation was quanti¢ed as described in Section 2. The residues undergoing CK2-catalyzed
phosphorylation are underlined. Values are means of at least three determinations with a standard error less than 15%.
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property exhibited by calmodulin, disappears when the full-
size proteins are replaced by synthetic peptides spanning their
phosphoacceptor sites. In fact, as shown in Table 1, phos-
phorylation of peptides derived from Rev, calmodulin and
I-2 as well as the standard peptide substrate R3A2DSD5 (rou-
tinely used for monitoring CK2 activity) is stimulated to a
similar extent in the presence of the L subunit.
Besides its absolute requirement for the L subunit, another
peculiarity of Rev phosphorylation is its inhibition by poly-
cationic compounds which are generally considered stimula-
tors of CK2 activity. As shown in Fig. 1, while polylysine
slightly increases the phosphorylation of I-2 and dramatically
enhances that of calmodulin by the CK2 holoenzyme, it exerts
a detrimental e¡ect on Rev phosphorylation. Phosphorylation
of Rev is also inhibited in a dose-dependent manner by sper-
mine, another polycation which is believed to be a physiolog-
ical activator of CK2 [31] (Fig. 2A) and which under compa-
rable conditions actually stimulates the phosphorylation of L-
casein. The e¡ects of spermine [11] and polylysine [8] are both
mediated by the L subunit of CK2. In contrast the CK2 in-
hibitor heparin directly a¡ects the catalytic subunit [21]. It
may be worth noting in this connection that the response of
Rev phosphorylation to heparin is regular (Fig. 2B).
It has been shown that stimulation of CK2 by polycations
re£ects, at least partially, their ability to interact with and
neutralize an acidic region in the N-terminal domain of the
L subunit, which exerts a down-regulating e¡ect by interacting
with the peptide substrate binding site of the K subunit [32].
Consequently a mutant of the L subunit in which two crucial
acidic residues of this region were replaced by neutral amino
acids displays both hyperstimulation of catalytic activity [6]
and reduced susceptibility to further stimulation by polylysine
[8]. As expected, this L subunit mutant hyperstimulates phos-
phorylation of the synthetic peptide R3A2DSD5 (Fig. 3B). In
contrast, the same mutant displays a reduced ability to stim-
ulate phosphorylation of Rev compared to the wild type sub-
unit (Fig. 3A).
In summary, the phosphorylation of Rev by CK2 is unique
in at least three respects : (i) it is fully dependent on the pres-
ence of the L subunit; (ii) it is up-regulated by acidic residues
of the L subunit that normally down-regulate CK2 activity;
Fig. 2. Inhibition of Rev phosphorylation (open symbols) by sper-
mine (A) and heparin (B). For the sake of comparison the phos-
phorylation of L-casein (¢lled symbols), which is enhanced by sper-
mine, is also shown. Conditions are those detailed in the legend of
Fig. 1 and in Section 2 except for the concentration of MgCl2
which was 2 mM. Phosphorylation is expressed as percent of con-
trols in the absence of e¡ectors, corresponding to 4.6 and 18.4 pmol
for Rev and L-casein, respectively. Identical results were obtained
with native CK2 puri¢ed from rat liver instead of the recombinant
holoenzyme reconstituted in vitro (not shown).
Fig. 3. Opposite e¡ects of mutant L55,57A on CK2-catalyzed phos-
phorylation of Rev (A) and of the synthetic peptide R3A2DSD5 (B).
Rev protein (2 Wg) and the synthetic peptide RRRAADSDDDDD
(100 WM) were phosphorylated under conditions described in the
legend to Fig. 1 by recombinant CK2 K subunit either alone or pre-
viously mixed with an equimolar amount of wild type or mutated
L subunit. The phosphorylation of Rev was determined after SDS^
PAGE while that of the synthetic peptide was evaluated by separa-
tion on phosphocellulose paper [30].
Fig. 4. Proposed conformational models of wild type Rev and Re-
vvloop. In A the schematic representation of wild type Rev is
shown with the highlighted structural helix 1-loop-helix 2 motif. Ba-
sic residues R38 and R39, replaced by leucine in the mutant
Rev38,39R-L, are underlined. Phosphoacceptor sites Ser-5 and Ser-8
are also indicated. In B the £exible model of the wild type Rev he-
lix-loop-helix motif allowing the simultaneous binding to the cata-
lytic site of CK2K and to the acidic domain of CK2L subunit is
proposed in comparison with the rigid, uninterrupted helix predicted
for mutant Revvloop. The secondary structures of wild type Rev
and Revvloop were predicted using the PHD sec method [37,38],
available over the Internet (http://dodo.cpmc.columbia.edu/predict-
protein/).
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(iii) it is inhibited, rather than stimulated by polycationic ef-
fectors.
The overall conformation of the Rev protein apparently
plays a role in conferring atypical responsiveness to L regu-
lation, as demonstrated by the observation that a synthetic
fragment of Rev including the phosphoacceptor sites (residues
1^26) is no longer dependent on the L subunit for e⁄cient
phosphorylation (see Table 1). Two structural features of
Rev that could account for its atypical mode of phosphory-
lation by CK2 are a basic stretch (residues 35^50) that has
been implicated in the observed stimulation of CK2 catalytic
activity by Rev [20] and could interact with the acidic cluster
in the N-terminal domain of the L subunit, and a helix 1-loop-
helix 2 motif that is likely to play a key role in conferring a
biologically active conformation [33,34]. Recent studies dem-
onstrated that the loop is essential for Rev function (D’Agos-
tino et al., unpublished results) and led to the proposal that it
acts as a £exible hinge that allows correct alignment of the
two helices, which might in turn place the polycation-like
basic stretch in close proximity to Ser-5 and Ser-8 (see Fig. 4).
To assess the in£uence these two structural motifs might
have on the phosphorylation of Rev by CK2, two mutants
in this regions were compared to wild type Rev for their
ability to undergo phosphorylation by the K subunit and ho-
loenzyme. The ¢rst mutant, named Rev38,39R-L, contains
leucines in place of the ¢rst pair of arginines of the basic
cluster. The second mutant, named Revvloop, has a deletion
encompassing the entire loop linking helices 1 and 2. This
mutation is predicted to give rise to a rigid uninterrupted helix
generated by the fusion of helices 1 and 2 (D’Agostino et al.,
unpublished results; see also Fig. 4). As shown in Table 2,
both mutants are ine⁄ciently phosphorylated by CK2 holo-
enzyme, although in the presence of the K subunit alone they
undergo a weak phosphorylation which is not detectable with
Rev wild type. These data corroborate the idea that the ter-
tiary structure of the protein plays a key role in the mecha-
nism by which Rev is recognized and/or phosphorylated by
CK2.
4. Discussion
Our ¢ndings outline a number of features that distinguish
Rev from other CK2 substrates studied thus far. First, Rev is
not phosphorylated to any appreciable extent by the isolated
catalytic subunit of CK2, in contrast to all other substrates
tested so far, toward which CK2K is constitutively active.
Consequently, phosphorylation of Rev by CK2 is entirely de-
pendent on the regulatory L subunits, which combine with the
catalytic subunits, yielding a very stable holoenzyme with the
heterotetrameric K2L2 structure [35]. Although strong up-reg-
ulation in the presence of the L subunit has been reported for
a few other substrates, e.g. CREB and MS2-E7 [36], the
nearly absolute requirement for the L subunit is unique to
Rev. Third, the acidic residues clustered in the N-terminal
domain of the L subunit, which are normally responsible for
down-regulation, are instead required for e⁄cient Rev phos-
phorylation. Fourth, phosphorylation of Rev by the CK2 ho-
loenzyme is inhibited by polybasic peptides and by poly-
amines which conversely behave as activators in the context
of all the other CK2 substrates tested thus far. Such a behav-
ior, especially as far as inhibition by spermine is concerned,
subverts our current opinion about polyamines, which are
considered physiological activators of CK2 [31]. This leads
to the prediction that under physiological conditions where
the concentration of spermine increases and consequently
the activity of CK2 toward most of its targets is enhanced,
the phosphorylation of HIV-1 Rev protein is conversely re-
pressed. Assuming that Rev phosphorylation is essential to
viral replication (yet to be proven), the above observation
could also have practical applications, as it suggests the pos-
sibility of arresting or inhibiting virus infection by increasing
the intracellular spermine concentration. It is also predictable
that conditions promoting deep oscillations in spermine con-
centration might impinge on the level of Rev phosphorylation
and possibly in£uence susceptibility to HIV-1 infection.
The unique behavior of Rev with respect to CK2-mediated
phosphorylation is dependent, at least in part, on its tertiary
structure. This conclusion is supported by two lines of evi-
dence: ¢rst, a 26-mer peptide encompassing the Rev phos-
phoacceptor site (Ser-5 and Ser-8) has lost the most peculiar
feature of Rev phosphorylation, namely the absolute require-
ment for the L subunit; secondly, phosphorylation of Rev by
the CK2 holoenzyme is dramatically reduced by two structur-
al modi¢cations (i.e. deletion of the loop and the 38,39R-L
mutation) which do not directly a¡ect the phosphoacceptor
site. It has to be assumed therefore that although the phos-
phoacceptor site ful¢ls the consensus for CK2 (S-x-x-D/E/Sp)
and consequently is readily phosphorylated by CK2K in the
context of the 1^26 peptide, the overall conformation of the
protein renders the site inaccessible or unsuitable in the ab-
sence of the L subunits.
Although the mechanism by which the L subunit assists Rev
phosphorylation is currently a matter of conjecture, a direct
interaction between the L subunit and Rev is strongly sup-
ported by the observation that a L subunit mutation which
up-regulates the basal catalytic activity of CK2 holoenzyme
(i.e. the ED55,57CAA substitution) is instead detrimental to
Rev phosphorylation. This suggests that a productive interac-
tion of Rev with the CK2 holoenzyme requires those acidic
residues of the L subunit which are otherwise committed to
down-regulation of the catalytic site. It is quite possible that
Rev’s basic cluster of residues at the beginning of helix 2
represents the counterpart to the acidic residues of the L sub-
unit, as the substitution of R38 and R39 by Leu greatly re-
duces its phosphorylation. This interaction may also represent
the mechanism by which Rev stimulates the basal activity of
the CK2 holoenzyme [20]: upon engagement with Rev, the
acidic cluster of the L subunit would no longer be available
for down-regulation. Likewise, inhibition of Rev phosphory-
lation by polycationic compounds can be explained by a com-
Table 2
Phosphorylation of wild type and mutated Rev protein by the K
catalytic subunit and by in vitro reconstituted CK2 holoenzyme
Substrate Phosphorylation rate (pmol) by
K K2L2
GST-Rev wild type N.D. 6.57
GST-Rev38,39R-L 0.34 0.50
GST-Revvloop 0.18 0.24
Wild type and mutated proteins (2 Wg) were phosphorylated and 32P
incorporation was quanti¢ed as described in the legend of Fig. 1.
N.D., not detectable as radiolabeled SDS^PAGE band. The data re-
fer to the mean of values obtained from three independent experi-
ments with S.D. not exceeding 13%.
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petitive mechanism that counteracts the interaction of Rev
with CK2L. Therefore, paradoxically, although normally
speci¢ed by a negatively charged consensus sequence on the
substrate, recognition of Rev by CK2 would also critically
require basic residues that are relatively far away from the
phosphoacceptor site along the primary structure. It is pre-
dictable however that in the folded structure of Rev these
basic residues are brought closer to the phosphorylatable res-
idues by the juxtaposition of helices 1 and 2, made possible by
the £exibility of the spacer loop (see Fig. 4). The detrimental
e¡ect of the deletion of this loop on Rev phosphorylation (see
Table 2) is quite consistent with this scenario: as outlined in
Fig. 4, this deletion is expected to give rise to an uninterrupted
K helix generated by the fusion of helices 1 and 2, with a
consequent gross alteration in the spatial relationship between
the phosphoacceptor site and the critical basic cluster. Intri-
guingly, this same deletion also destroys Rev function in vivo
(D’Agostino et al., unpublished results). Based on this obser-
vation, in conjunction with the in vivo occurrence of Rev
phosphorylation at the same residues a¡ected in vitro by
CK2 [16] it would be tempting to hypothesize a correlation
between CK2-mediated phosphorylation and Rev functional
activity. However, no direct evidence for such a functional
correlation is available to date. On the other hand, the possi-
bility should also be taken into account that phosphorylation
by CK2 a¡ects other properties of Rev, such as stability or
propensity to multimerize, by analogy with the observed con-
sequences of Rev phosphorylation at another site [39]. In
conclusion, while a cause^e¡ect relationship between Rev
phosphorylation and its biological activity remains to be es-
tablished, our data show that CK2-mediated phosphorylation
and functional activity of Rev have similar tertiary structure
requirements and are controlled by overlapping domains.
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